Abstract
Lobelane, a chemically defunctionalized saturated analog of lobeline, has increased selectivity for the vesicular monoamine transporter 2 (VMAT2) compared with the parent compound. Lobelane inhibits methamphetamine-evoked dopamine (DA) release and decreases methamphetamine self-administration. Unfortunately, tolerance develops to the ability of lobelane to decrease these behavioral effects of methamphetamine. Lobelane has low water solubility, which is problematic for drug development. The aim of the current study was to determine the pharmacological effect of replacement of the N-methyl moiety with a chiral N-1,2-dihydroxypropyl (N-1,2-diol) moiety, which enhances water solubility, altering the configuration of the N-1,2-diol moiety and incorporating phenyl ring substituents into the analogs. To determine VMAT2 selectivity, structure-activity relationships also were generated for inhibition of DA and serotonin transporters. Analogs with the highest potency for inhibiting DA uptake at VMAT2 and at least 10-fold selectivity were evaluated further for ability to inhibit methamphetamine-evoked DA release from superfused striatal slices. (R)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-793A), the (R)-4-methoxyphenyl-N-1,2-diol analog, and (R)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol (GZ-794A), the (R)-1-naphthyl-N-1,2-diol analog, exhibited the highest potency (Ki ∼30 nM) inhibiting VMAT2, and both analogs inhibited methamphetamine-evoked endogenous DA release (IC50 = 10.6 and 0.4 μM, respectively). Thus, the pharmacophore for VMAT2 inhibition accommodates the N-1,2-diol moiety, which improves drug-likeness and enhances the potential for the development of these clinical candidates as treatments for methamphetamine abuse.
Footnotes
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA13519, DA016176].
The University of Kentucky holds patents on lobeline and the analogs described in the current work, which have been licensed by Yaupon Therapeutics, Inc. A potential royalty stream to D.B.H., G.Z., P.A.C., and L.P.D. may occur consistent with University of Kentucky policy. Both P.A.C. and L.P.D. are founders of, and have financial interest in, Yaupon Therapeutics, Inc.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.111.184770.
-
ABBREVIATIONS:
- DAT
- dopamine transporter
- 5-HT
- 5-hydroxytryptamine (serotonin)
- ANOVA
- analysis of variance
- DA
- dopamine
- DTBZ
- dihydrotetrabenazine
- EC
- electrochemical detection
- GBR 12909
- 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
- GZ-252C
- para-methoxyphenyl lobelane
- GZ-745A
- (R)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol
- GZ-745B
- (S)-3-(2,6-cis-diphenethylpiperidin-1-yl)propane-1,2-diol
- GZ-790A
- (R)-3-[2,6-cis-di(3-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-790B
- (S)-3-[2,6-cis-di(3-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-791A
- (R)-3-[2,6-cis-di(3-fluorophenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-791B
- (S)-3-[2,6-cis-di(3-fluorophenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-792A
- (R)-3-[2,6-cis-di(2-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-792B
- (S)-3-[2,6-cis-di(2-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-793A
- (R)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-793B
- (S)-3-[2,6-cis-di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-794A
- (R)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol
- GZ-794B
- (S)-3-[2,6-cis-di(1-naphthylethyl)piperidin-1-yl]propane-1,2-diol
- GZ-795A
- (R)-3-[2,6-cis-di(2,4-dichlorophenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-795B
- (S)-3-[2,6-cis-di(2,4-dichlorophenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-796A
- (R)-3-[2,6-cis-di(4-biphenylethyl)piperidin-1-yl]propane-1,2-diol
- GZ-796B
- (S)-3-[2,6-cis-di(4-biphenylethyl)piperidin-1-yl]propane-1,2-diol
- GZ-797A
- (R)-3-[2,6-cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol
- GZ-797B
- (S)-3-[2,6-cis-di(3,4-methylenedioxyphenethyl)piperidin-1-yl]propane-1,2-diol
- HPLC
- high-performance liquid chromatography
- N-1,2-diol
- N-1,2-dihydroxypropyl
- Ro-4-1284
- (2R,3S,11bS)-2-ethyl-3-isobutyl-9,10-dimethoxy-2,2,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol
- SAR
- structure-activity relationship
- SERT
- serotonin transporter
- UKCP-110
- cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride
- UKMH-106
- (3Z,5Z)-3,5-bis(2,4-dichlorobenzylidene)-1-methylpiperidine
- VMAT2
- vesicular monoamine transporter 2.
- Received June 3, 2011.
- Accepted July 20, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
